Skip to main content
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TARS ISIN · US87650L1035 US Manufacturing
Filings indexed 576 across all filing types
Latest filing 2022-12-16 Director's Dealing
Country US United States of America
Listing US TARS

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com/

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for diseases with limited treatment options. The company's initial focus is on eye care. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of potential treatments for other conditions with high unmet needs, including ocular rosacea, Lyme disease prevention, and other indications across dermatology and infectious diseases.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-12-16 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 1, 2022, reporting changes in the company's board of directors and senior management. It details the resignation of the Chairperson, appointment of a new Chairperson and Lead Independent Director, and related compensatory arrangements. There is no financial data or report content, only management changes. According to the filing definitions, this fits the category of Board/Management Information (MANG). The document length is 5351 characters, sufficient to contain substantive information about management changes rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2022-12-07 English
FORM 4
Director's Dealing
2022-12-06 English
FORM 4
Director's Dealing
2022-12-06 English
FORM 4
Director's Dealing
2022-12-06 English
FORM 4
Director's Dealing
2022-12-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.